Liquidia Corporation LQDA
Set alert
As of Nov 3, 2:50 PM ET
- YTD
- +21.43%
- 1 year
- +66.06%
- Open
- 41.69
- Prev close
- 41.85
- Mkt cap
- 3.75B
- Vol
- 987.58K
- Avg vol
- 3.40M
- EPS
- 1.39
- P/E
- 30.14
- Div yield
- 0.00%
More statistics
- Low
- 41.58
- High
- 43.37
- Forward P/E
- 19.13
- Beta
- 0.41
- Short ratio
- 2.89
- Inst. own
- 81.79%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 2, 2026
- 50-d avg
- 52.99
- 200-d avg
- 54.30
- 1y target
- 54.38
5Y chart
Events in this range
- Aug 12, 2025Earnings: -0.49; estimate -0.43; surprise -13.95%
- Nov 3, 2025Earnings: -0.04; estimate -0.45; surprise 91.11%
- Mar 5, 2026Earnings: 0.15; estimate 0.08; surprise 87.5%
- May 11, 2026Earnings: 0.52; estimate 0.34; surprise 52.94%
- Aug 12, 2026Earnings: 0.74; estimate 0.7; surprise 5.71%
- Oct 2, 2026Downgrade: Wells Fargo · Overweight → Equal-Weight
- Oct 14, 2026Rating: BTIG · Neutral → Buy
- Oct 14, 2026Rating: Needham · Buy → Buy
- Oct 14, 2026Rating: Wells Fargo · Equal-Weight → Equal-Weight
- Oct 14, 2026Rating: LifeSci Capital · Market Perform → Outperform
- Oct 15, 2026Rating: HC Wainwright & Co. · Buy → Buy
- Nov 2, 2026Earnings: —; estimate 0.96; surprise —%
Signals (75)
| Name | Date | Ago |
|---|---|---|
| SMA: Bearish | Sep 28, 2026 | 1 month ago |
| RSI: Oversold | Sep 28, 2026 | 1 month ago |
| MACD: Sell Signal | Aug 17, 2026 | 2 months ago |
| SMA: Bearish | Aug 10, 2026 | 2 months ago |
| MACD: Buy Signal | May 11, 2026 | 5 months ago |
| RSI: Overbought | May 11, 2026 | 5 months ago |
| SMA: Bullish | Mar 30, 2026 | 7 months ago |
| SMA: Bearish | Feb 16, 2026 | 8 months ago |
| MACD: Sell Signal | Feb 16, 2026 | 8 months ago |
| RSI: Overbought | Jan 12, 2026 | 9 months ago |
| RSI: Overbought | Nov 24, 2025 | 11 months ago |
| MACD: Buy Signal | Nov 10, 2025 | 11 months ago |
| SMA: Bullish | Oct 27, 2025 | 1 year ago |
| MACD: Sell Signal | Oct 13, 2025 | 1 year ago |
| SMA: Bearish | Sep 22, 2025 | 1 year ago |
| RSI: Overbought | Aug 11, 2025 | 1 year ago |
| SMA: Bullish | Jul 21, 2025 | 1 year ago |
| MACD: Buy Signal | Jul 21, 2025 | 1 year ago |
| SMA: Bullish | Jul 14, 2025 | 1 year ago |
| SMA: Bearish | Jun 16, 2025 | 1 year ago |
Newest 20 of 75.
Key statistics
- Market cap
- 3.75B
- Enterprise value
- 3.93B
- Trailing P/E
- 30.11
- Forward P/E
- 19.13
- PEG ratio
- 0.00
- Price / sales
- 8.31
- Price / book
- 19.11
- EPS (TTM)
- 1.39
- Beta
- 0.41
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 30.74%
- Revenue (TTM)
- 450.91M
- Revenue growth
- 1842.70%
- Free cash flow
- 74.30M
- Total cash
- 284.18M
- Total debt
- 182.90M
- Return on equity
- 131.82%
- Shares outstanding
- 89.51M
- Short % of float
- 23.98%
- 50-day average
- 52.99
- 200-day average
- 54.30
Analyst view
- Target (low)
- 33.00
- Target (mean)
- 54.38
- Target (high)
- 70.00
- Strong buy2
- Buy4
- Hold2
- Sell0
- Strong sell0
Next earnings
Nov 2, 2026
Expected Nov 2, 2026. Consensus EPS estimate 0.97571.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 2, 2026 | Sep 30, 2026 | 0.96 | — | — | — |
| Aug 12, 2026 | Jun 30, 2026 | 0.70 | 0.74 | +0.04 | +5.71% |
| May 11, 2026 | Mar 31, 2026 | 0.34 | 0.52 | +0.18 | +52.94% |
| Mar 5, 2026 | Dec 31, 2025 | 0.08 | 0.15 | +0.07 | +87.50% |
| Nov 3, 2025 | Sep 30, 2025 | -0.45 | -0.04 | +0.41 | +91.11% |
| Aug 12, 2025 | Jun 30, 2025 | -0.43 | -0.49 | -0.06 | -13.95% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 15, 2026 | HC Wainwright & Co. | main | Buy | Buy |
| Oct 14, 2026 | LifeSci Capital | up | Market Perform | Outperform |
| Oct 14, 2026 | Wells Fargo | main | Equal-Weight | Equal-Weight |
| Oct 14, 2026 | Needham | main | Buy | Buy |
| Oct 14, 2026 | BTIG | up | Neutral | Buy |
| Oct 2, 2026 | Wells Fargo | down | Overweight | Equal-Weight |
About Liquidia Corporation
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for rare cardiopulmonary diseases in the United States. The company's lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). It also provides Remodulin, a treprostinil injection administered through continuous intravenous and subcutaneous infusion; and develops L606, an investigational liposomal formulation of treprostinil which is in phase III clinical trial for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). In addition, the company offers PRINT technology which allows to engineer and manufacture uniform drug particles with precise control over the size, three-dimensional geometric shape, and chemical composition of the particles. It has a license agreement with Pharmosa Biopharm Inc to develop and commercialize L606, an inhaled sustained-release formulation of Treprostinil for the treatment of PAH and PH-ILD; Vectura; The University of North Carolina at Chapel Hill; GlaxoSmithKline; Alcon Inc; and promotion Agreement with Sandoz. Liquidia Corporation was founded in 2004 and is based in Morrisville, North Carolina.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Country
- United States
- Website
- liquidia.com
News
- Liquidia Corporation to Report Third Quarter 2026 Financial Results on November 10, 2026
- Liquidia Gears Up to Report Q3 Earnings: What Can Investors Expect?
- Liquidia Corporation (LQDA) Earnings Expected to Grow: Should You Buy?
- Range Resources, Xtend AI Robotics, Oruka Therapeutics And Other Big Stocks Moving Higher On Monday
- Liquidia Corporation Investigation Continues: Investors May Contact Kirby McInerney LLP, a Securities Fraud Law Firm, If You Lost Money on Your LQDA Investments
- HC Wainwright & Co. Maintains Buy on Liquidia, Raises Price Target to $65
- LQDA Settles UTHR Disputes for $380.7M, Limits Yutrepia Label
- Liquidia shares surge 25% as settlement ends United Therapeutics litigation
- 12 Health Care Stocks Moving In Wednesday's Intraday Session
- Nasdaq Dips Over 400 Points; Bank of America Shares Tumble After Q3 Results
Your note
Sign in to keep a note on LQDA — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ADAIR JASON | Officer | Sale | Oct 25, 2026 | 177,269 |
| BLOCH STEPHEN M. | Director | Sale | Jul 22, 2026 | 0 |
| BOYLE DANA | Officer | Sale | Oct 25, 2026 | 164,028 |
| CALIGAN PARTNERS L,P. | Beneficial Owner of more than 10% of a Class of Security | Purchase | May 18, 2026 | 0 |
| JEFFS ROGER A | Chief Executive Officer | Sale | Oct 11, 2026 | 2,214,110 |
| JOHNSON DAVID EDWARD | Director and Beneficial Owner of more than 10% of a Class of Security | Stock Award(Grant) | Jun 15, 2026 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 12.05% | 10,788,586 | 451.50M | Jun 29, 2026 |
| Farallon Capital Management LLC | 9.35% | 8,365,038 | 350.08M | Jun 29, 2026 |
| Caligan Partners, LP | 9.07% | 8,118,892 | 339.78M | Jun 29, 2026 |
| Findell Capital Management LLC | 3.91% | 3,502,112 | 146.56M | Jun 29, 2026 |
| Vanguard Capital Management LLC | 3.51% | 3,139,183 | 131.37M | Jun 29, 2026 |
| State Street Corporation | 3.39% | 3,030,395 | 126.82M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| iShares Trust-iShares Core S&P Small-Cap ETF | 4.94% | 4,424,930 | 185.18M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 2.52% | 2,259,289 | 94.55M | Jun 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 2.04% | 1,826,128 | 76.42M | Sep 29, 2026 |
| Invesco Exchange-Traded Fund Trust-Invesco S&P SmallCap Momentum ETF | 0.94% | 841,088 | 35.20M | Sep 29, 2026 |
| Capitol Series Trust-FullerThaler Behavioral Small-Cap Growth Fund | 0.91% | 812,800 | 34.02M | Jun 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 0.90% | 805,880 | 33.73M | Jun 29, 2026 |